Dapagliflozin: brand names and study card

Dapagliflozin — SGLT2 inhibitor. Study the mechanism, listed uses and warnings from the US label on one sourced card.

Generic name: Dapagliflozin
Brands: Farxiga
Class: SGLT2 inhibitor
Mechanism: Inhibits SGLT2 in the proximal renal tubule, reducing filtered glucose reabsorption and increasing urinary glucose excretion.
Used for: Adjunct to diet and exercise for glycemic control in adults with type 2 diabetes; this use is not recommended when eGFR is below 45 mL/min/1.73 m²; Reduction of heart-failure hospitalization in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors
Common side effects: Female genital mycotic infections; Nasopharyngitis; Urinary tract infections
Warnings: Ketoacidosis; Volume depletion; Genitourinary infections / Fournier's gangrene
Interactions: Insulin or insulin secretagogues; Lithium

Label date: 20260908 · For learning, not clinical decisions. US label and brand information; always consult the current source.

Source snapshot checked: 2026-10-21. The source document and selected fields were compared. The complete card has not had an independent clinical review.

Practice

Pronunciation

Dapagliflozin: dap-a-gli-FLOE-zin

Shared name ending: -gliflozin · Empagliflozin

Pronunciation is shown for the US English generic name. A name ending is a memory cue, not a classification rule.

Other drugs in the same class

SGLT2 inhibitors: Empagliflozin

Body system

Endocrine · 27 Drug cards

Compare with related cards

Empagliflozin

Same class family: SGLT2 inhibitors

Mechanism: Inhibits renal SGLT2, reducing glucose reabsorption and increasing urinary glucose excretion; also reduces sodium reabsorption and increases sodium delivery to the distal tubule.

On both cards: Common side effects — Female genital mycotic infections; Urinary tract infections · Warnings — Ketoacidosis; Volume depletion · Interactions — Insulin or insulin secretagogues; Lithium

Only on the Empagliflozin card: Used for — Adjunct to diet and exercise for glycemic control in adults and children aged 10 years and older with type 2 diabetes; not recommended for this use when eGFR is below 30 mL/min/1.73 m²; Reduction of cardiovascular death and heart-failure hospitalization in adults with heart failure; Reduction of kidney decline, end-stage kidney disease, cardiovascular death and hospitalization in adults with chronic kidney disease at risk of progression; the label excludes specified polycystic and immunosuppression-treated kidney-disease populations from recommended use; Reduction of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease · Warnings — Genitourinary infections incl. Fournier's gangrene · Interactions — Diuretics

An item counts as shared only when both cards use the same wording. If a card does not list an item, that is not a statement that the effect never occurs.